Scarica l'app Stockscreener
13.74
5.18%
-0.75
Dopo l'orario di chiusura:
13.76
0.02
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$14.49
Aprire:
$14.56
Volume 24 ore:
2.16M
Relative Volume:
4.10
Capitalizzazione di mercato:
$558.06M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.6784
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-14.76%
1M Prestazione:
-13.04%
6M Prestazione:
+1.55%
1 anno Prestazione:
-77.90%
Intervallo 1D:
$13.65
$14.83
Intervallo di 1 settimana:
$13.65
$16.18
Portata 52W:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.74 | 612.89M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares - MarketBeat
Is Keros Therapeutics Inc. stock poised for growthJuly 2025 Outlook & Comprehensive Market Scan Reports - newser.com
Why Keros Therapeutics Inc. stock remains undervaluedJuly 2025 Recap & Precise Swing Trade Alerts - newser.com
Earnings visualization tools for Keros Therapeutics Inc.Weekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Keros Therapeutics Sparks Market Interest With Nasdaq Futures - Kalkine Media
Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m By Investing.com - Investing.com UK
Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com
Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
What hedge fund activity signals for Keros Therapeutics Inc. stockJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.July 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
What momentum indicators show for Keros Therapeutics Inc. stockQuarterly Trade Report & Smart Swing Trading Techniques - newser.com
Keros Therapeutics Announces Plan for Return of $375 Million In Excess Capital - citybiz
Can volume confirm reversal in Keros Therapeutics Inc.Buy Signal & Free Accurate Trade Setup Notifications - newser.com
Keros Therapeutics, Inc. Announces Board and Committee Changes, Effective October 15, 2025 - MarketScreener
Using flow based indicators on Keros Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
Keros up after acquiring major investors' shares at premium; unveils $194 million buyback plan - TradingView
Keros Therapeutics Plans Major Buyback And Tender Offer - Finimize
Keros Therapeutics (KROS) Announces Share Repurchase Agreements - GuruFocus
Keros Therapeutics Announces Board Changes - TradingView
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital - GlobeNewswire
$375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025 - Stock Titan
Keros Therapeutics Inc. stock trendline breakdown2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Published on: 2025-10-14 03:37:04 - newser.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Can machine learning forecast Keros Therapeutics Inc. recoveryJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
How to recover losses in Keros Therapeutics Inc. stock2025 Trading Recap & Scalable Portfolio Growth Methods - newser.com
Historical volatility pattern of Keros Therapeutics Inc. visualizedJobs Report & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-13 08:49:09 - newser.com
Will breakout in Keros Therapeutics Inc. lead to full recoveryInsider Selling & High Win Rate Trade Tips - newser.com
Forecasting Keros Therapeutics Inc. price range with options dataTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
What analysts say about Keros Therapeutics Inc stockPrice Support Zones & High Yield Trading Signals - earlytimes.in
Keros Therapeutics Inc. stock daily chart insightsMarket Volume Summary & Long Hold Capital Preservation Tips - newser.com
Published on: 2025-10-10 05:54:47 - newser.com
Weiss Ratings Reaffirms "Sell (D)" Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance
Public Employees Retirement System of Ohio Purchases Shares of 26,103 Keros Therapeutics, Inc. $KROS - MarketBeat
Can Keros Therapeutics Inc. recover in the next quarterMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Can Keros Therapeutics Inc. rally from current levelsGap Down & Weekly Market Pulse Alerts - newser.com
Will Keros Therapeutics Inc. bounce back from current supportQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
How to interpret RSI for Keros Therapeutics Inc. stockWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):